Sanofi’s new booster shot induces a significant rise in antibodies against worrisome corona variants. This is apparent from the results of two studies, reports the French pharmaceutical company. The jab was developed in collaboration with the British pharmaceutical company GSK.
The new candidate booster shot from Sanofi-GSK performs particularly well against the omikron variant: it generates twice as many antibodies as the previous candidate booster shot, according to a study with 1,500 participants.
A study with 247 participants points to the same trend. The booster shot candidate generates a higher immune response in people who received two shots of the Pfizer/BioNTech corona vaccine than the Pfizer/BioNTech booster pick itself and the previous booster shot candidate from Sanofi-GSK. The new candidate also produced the most antibodies against the omikron variant of the coronavirus.
The new generation booster shot candidate was well tolerated in both studies. Sanofi-GSK will now submit the results to the competent authorities and hopes for approval by the end of the year.
Free unlimited access to Showbytes? Which can!
Log in or create an account and never miss a thing from the stars.